Posted by Michael Wonder on 29 Oct 2024
Allogene Therapeutics receives FDA regenerative medicine advanced therapy designation for ALLO-316, an AlloCAR T investigational product for adult patients with advanced or metastatic renal cell carcinoma
29 October 2024 - ALLO-316 was previously granted fast track designation in March 2022 by the US FDA.
Allogene Therapeutics today announced that the US FDA granted regenerative medicine advanced therapy designation to ALLO-316 for the treatment of adult patients with CD70 positive advanced or metastatic renal cell carcinoma.
